The identification of the amplified genes CENPF, GMNN, and CDK13 in tumors provides new insight into the carcinogenesis process, and suggests that these genes can be used as novel cancer markers for the development of diagnostic, prognostic, and/or targeted therapies. This evidence concerns the gene CDK13 and cancer.